Bio Pharma Dive
MAY 6, 2025
A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.
Pharmaceutical Technology
MAY 6, 2025
Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To rise to these challenges, the biopharma industry continues to develop innovative strategies to bring vital therapies swiftly to rare disease patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
MAY 6, 2025
The Nudge Unit at Penn Medicine opened registration and abstract submissions for the 2025 Nudges in Health Care Symposium. The event is “focused on exploring the application of behavioral economics principles and nudges in healthcare settings.” The Nudge Unit is supported by Center for Health Care Transformation and Innovation and thePenn Center for Health Incentives and Behavioral Economics.
XTalks
MAY 6, 2025
Gastrointestinal (GI) disorders pose major challenges in modern healthcare. In the US, nearly 45 million adults suffer from nonerosive gastroesophageal reflux disease (GERD) , while more than 15 million receive prescription treatments for its erosive form. Nonerosive GERD shows typical reflux symptoms without visible esophageal damage, whereas erosive GERD causes clear injury to the esophageal lining.
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance trainings aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, relevant, and maybe even enjoyable! Join expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training programs. You’ll discover creative strategies to turn traditionally dry topics into meaningful learning experiences that resonate and drive real change.
Pharmaceutical Technology
MAY 6, 2025
The options are for the freeze-dried version of Bavarian Nordics Jynneos, a formulation that allows easier stockpiling.
Bio Pharma Dive
MAY 6, 2025
Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing obstacle to large acquisitions.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
MAY 6, 2025
The appointment of Prasad as head of the FDA’s Center for Biologics Evaluation and Research sent shares in developers of vaccines and genetic medicines tumbling.
Pharmaceutical Technology
MAY 6, 2025
Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research and manufacturing capabilities.
Bio Pharma Dive
MAY 6, 2025
Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its workforce.
Pharmaceutical Technology
MAY 6, 2025
Recursion Pharmaceuticals has narrowed its drug development pipeline as it seeks to reduce costs and reprioritise resources.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Pharma Times
MAY 6, 2025
New initiative aims to accelerate diagnosis and ease NHS pressures
Pharmaceutical Technology
MAY 6, 2025
Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) of 2025 from $18.8bn in Q4 2024 to $37.7bn, according to leading data and analytics company GlobalDatas Pharmaceutical Intelligence Center Deals Database.
Pharma Times
MAY 6, 2025
Company seeks approval for new schedules to improve patient convenience
Pharmaceutical Technology
MAY 6, 2025
Veraxa Biotech has entered a joint discovery partnership with OmniAb for developing a bispecific antibody drug conjugate programme.
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Drug Channels
MAY 6, 2025
Two weeks ago, Senator Bill Cassidynow chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP)dropped a must-read, eyebrow-raising report on the out-of-control 340B Drug Pricing Program. (Link below.) The report reveals previously confidential information showing how billions are funneled to health systems and pharmacieswith manufacturers unable to follow the flow.
Pharmaceutical Technology
MAY 6, 2025
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), once focused on treating diabetes and obesity, are now emerging as potential treatments for a broader range of chronic conditions, including metabolic dysfunction-associated steatohepatitis and Alzheimers disease.
pharmaphorum
MAY 6, 2025
Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients
Pharmaceutical Technology
MAY 6, 2025
Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with Stelara.
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
pharmaphorum
MAY 6, 2025
A potentially pivotal trial PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data
Pharmaceutical Technology
MAY 6, 2025
Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.
pharmaphorum
MAY 6, 2025
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rob Abbott, CEO and executive director of ISPOR the leading professional society for HEOR globally about the ins and outs and trends of HEOR.
Pharmaceutical Commerce
MAY 6, 2025
Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
pharmaphorum
MAY 6, 2025
The EU has announced a 500m to convince top scientific talent from around the world to relocate to Europe's "free and open" research environment
Pharmaceutical Commerce
MAY 6, 2025
Rob Truckenmiller, CEO of PharmaCord, talks about the companys role in patient services, trends he sees shaping patient access to healthcare in the U.S., and a recent patient-centric merger.
Pharma Marketing Network
MAY 6, 2025
The pharma industry is undergoing a seismic transformation. As 2025 unfolds, traditional business models are giving way to data-driven innovation, personalized care, and integrated digital ecosystems. Stakeholders across the healthcare spectrum must not only adapt to changethey must anticipate it. Imagine steering a ship through unpredictable currents.
Pharmaceutical Commerce
MAY 6, 2025
Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies and support future payment strategies.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
MAY 6, 2025
Incorporating NGS technology early in the drug development process lays the foundation for CDx development, and taking a co-development approach helps ensure patients have access to emerging therapies as soon as they are approved, positively impacting cancer patient outcomes while minimising the risks from inappropriate treatment.
Pharmaceutical Commerce
MAY 6, 2025
As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders become more prevalent, self-injectables are here to stay.
Pharma Tutor
MAY 6, 2025
Drug-Drug interactions : keep it up with challenges admin Tue, 05/06/2025 - 16:08 Drug-Drug interactions are identified through a combination of clinical observation, scientific research, pharmacological knowledge, and the use of specialized tools. In clinical practice, healthcare providers assess the risk of interactions by reviewing a patients complete medication list, including prescription drugs, over-the-counter products, and supplements.
Drug Patent Watch
MAY 6, 2025
"The Future of Medicine is Not Just About the Cure, But Also About the Business of It. New research suggests that the success of a new medication is often determined long before it reaches the market. At DrugPatentWatch, we're taking a closer look at the data and uncovering the secrets to predicting a drug's market potential. From patent filings to clinical trial results, we're breaking down the key indicators that can make or break a new medication's success.
Expert insights. Personalized for you.
210 
Let's personalize your content